  Activating JAK2 point mutations are implicated in the pathogenesis of myeloid and lymphoid malignancies , including high-risk B-cell acute lymphoblastic leukemia<disease> ( B-ALL). In preclinical studies , treatment of JAK2 mutant leukemias<disease> with type I JAK2 inhibitors ( e.g. , Food and Drug Administration ( FDA)- approved ruxolitinib) provided limited single-agent responses , possibly due to paradoxical JAK2